Rheumatoid arthritis therapeutic tetrapeptide

Drug Profile

Rheumatoid arthritis therapeutic tetrapeptide

Alternative Names: PTL 0401

Latest Information Update: 13 Jul 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Acambis; BTG
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 13 Jul 1998 Discontinued-II for Rheumatoid arthritis in United Kingdom (Intra-articular)
  • 23 Oct 1997 Phase-II clinical trials for Rheumatoid arthritis in United Kingdom (Intra-articular)
  • 11 Jul 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top